ArticleJournal of industrial microbiology & biotechnology2015
Muconic acid production from glucose using enterobactin precursors in Escherichia coli.
Article in Journal of industrial microbiology & biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- Recent advances of muconic acid production using microbial synthetic biology.Archives of microbiology · 2025Review
- Characterization of Catechol-1,2-Dioxygenase (Acdo1p) FromFrontiers in microbiology · 2022Article
- Recent Advances in Microbial Production ofBiomolecules · 2020Review
- Metabolic engineering of Escherichia coli for shikimate pathway derivative production from glucose-xylose co-substrate.Nature communications · 2020Article
- Corynebacterium Cell Factory Design and Culture Process Optimization for Muconic Acid Biosynthesis.Scientific reports · 2018Article
- Metabolic Engineering of the Shikimate Pathway for Production of Aromatics and Derived Compounds-Present and Future Strain Construction Strategies.Frontiers in bioengineering and biotechnology · 2018Article
- Lignin Valorization: Two Hybrid Biochemical Routes for the Conversion of Polymeric Lignin into Value-added Chemicals.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muconic acid (MA) is a promising bulk chemical due to its extensive industrial applications in the production of adipic acid and other valuable, biodegradable intermediates. MA is heretofore mainly produced from petrochemicals by organic reactions which are not environmentally friendly or renewable. Biological production processes provide a promising alternative for MA production. We designed an artificial pathway in Escherichia coli for the biosynthesis of MA using the catechol group of 2,3-dihydroxybenzoate, an intermediate in the enterobactin biosynthesis pathway. This approach consists of two heterologous microbial enzymes, including 2,3-dihydroxybenzoate decarboxylase and catechol 1,2-dioxygenase. The metabolic flow of carbon into the heterologous pathway was optimized by increasing the flux from chorismate through the enterobactin biosynthesis pathway and by regulating the shikimate pathway. Metabolic optimization enabled a concentration of 605.18 mg/L of MA from glucose in a shaking flask culture, a value nearly 484-fold higher than that of the initial recombinant strain. The results indicated that the production of MA from this pathway has the potential for further improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.